It's been nearly five years since Moderna (NASDAQ: MRNA) emerged as a biotech industry disruptor, with its COVID-19 vaccine ...

Wealthfront Advisers LLC lowered its stake in shares of Moderna, Inc. (NASDAQ:MRNA – Free Report) by 84.4% during the fourth quarter, according to the company in its most recent disclosure with the ...

Moderna sports a $13 billion market cap but all the cash on ... In addition to vaccines it markets now, shots to prevent flu, ...

State-of-the-art mobile research units are set to break down barriers to health and care research participation in two coastal r ...

Barclays 27th Annual Global Healthcare Conference March 11, 2025 1:30 PM ETCompany ParticipantsRose Loughlin - EVP of ...

Mutual of America Capital Management LLC trimmed its position in Moderna, Inc. (NASDAQ:MRNA – Free Report) by 2.6% during the ...

pharmaceutical company Moderna, and EMS Healthcare, as part of the NOVA 301 trial – a phase 3 clinical trial investigating the safety and effectiveness of a vaccine preventing the winter vomiting bug.

The government has released the most recent norovirus statistics for the UK, following a warning from the UKHSA last week that the country could be on the brink of a second wave of the virus.

Moderna recently experienced a notable 10% price increase over the last week amidst significant legal and financial developments. Genevant Sciences and Arbutus Biopharma have expanded their patent ...